State Street Corporation (NYSE: STT) discloses 5.3% ownership in Corvus Pharmaceuticals
Rhea-AI Filing Summary
State Street Corporation, through its investment management subsidiaries, reports beneficial ownership of common stock of Corvus Pharmaceuticals, Inc..
State Street reports beneficial ownership of 4,474,091 shares of Corvus common stock, representing 5.3% of the class. It has shared voting power over 4,373,218 shares and shared dispositive power over 4,474,091 shares, with no sole voting or dispositive power.
Positive
- None.
Negative
- None.
Key Figures
Beneficially owned shares: 4,474,091 shares
Percent of class: 5.3%
Shared voting power: 4,373,218 shares
+3 more
6 metrics
Beneficially owned shares
4,474,091 shares
Common stock of Corvus Pharmaceuticals beneficially owned by State Street
Percent of class
5.3%
Portion of Corvus Pharmaceuticals common stock class held by State Street
Shared voting power
4,373,218 shares
Shares over which State Street has shared power to vote or direct the vote
Shared dispositive power
4,474,091 shares
Shares over which State Street has shared power to dispose or direct disposition
Sole voting power
0 shares
Shares over which State Street has sole power to vote
Sole dispositive power
0 shares
Shares over which State Street has sole power to dispose
Key Terms
beneficially owned, shared voting power, shared dispositive power, parent holding company, +1 more
5 terms
beneficially owned financial
"Ownership (a) | Amount beneficially owned: 4474091.00"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
parent holding company financial
"subsidiary which acquired the security being reported on by the parent holding company"
investment company financial
"shareholders of an investment company registered under the Investment Company Act of 1940"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What percentage of Corvus Pharmaceuticals (CRVS) does State Street own?
State Street Corporation reports owning 5.3% of Corvus Pharmaceuticals (CRVS) common stock, based on 4,474,091 shares beneficially owned as disclosed in the Schedule 13G filing.
Which State Street entities are involved in managing CRVS holdings?
The filing identifies SSGA Funds Management, Inc. and several State Street Global Advisors entities as investment advisers involved with Corvus Pharmaceuticals (CRVS) holdings, all under the State Street Corporation umbrella.
Who signed the Schedule 13G for Corvus Pharmaceuticals (CRVS)?
The Schedule 13G was signed by Elizabeth Schaefer, Senior Vice President, Chief Accounting Officer of State Street Corporation, dated 08/07/2026, on behalf of the reporting person.